Q3 Revenue Slips 2.4%, Adjusted Result Swings to Loss; $20M Cost Cuts and $15M Buyback Boost Announced
INGN sits 29% above its 52-week low of $5.045.
Summary
Inogen posted Q3 2026 revenue from continuing operations of $77.2 million, down 2.4% year over year, with U.S. sales up 3.8% offset by a 9.0% drop internationally. The bottom line deteriorated sharply: GAAP loss from continuing operations widened to $16.2 million from $3.6 million, and adjusted results flipped to a $0.4 million loss from $1.2 million of adjusted earnings a year ago, dragged by a $10.6 million impairment charge and gross margin slipping to 44.1% from 45.7%. Management guided Q4 revenue to $65-68 million and full-year 2026 to $298-301 million, with a full-year adjusted loss from continuing operations of $7-8 million. Alongside the print, the company launched a cost reduction program targeting roughly $20 million of annualized savings by the end of 2027 and raised its buyback authorization by $15 million to $45 million. The quarter reflects the completed November 2 divestiture of the U.S. oxygen rental business to Rotech for up to $24.8 million, which recasts the rental results as discontinued operations and resets the revenue base. This is the first report under new CEO Andy Reding, whose appointment was announced separately today; the weak adjusted result and soft Q4 guide are the numbers that matter for the stock.
At the time of this announcement, INGN was trading at $6.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $179.7M. The 52-week trading range was $5.05 to $8.14. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: BusinessWire.